Skip to main content

Table 1 Background characteristics of patients

From: Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients

Patients 40
Age, median [range] 67 [33–78]
Sex, male (%) 15 (37.5)
BW (kg), median [range] 58.0 [35.3–97.1]
Histopathology, follicular (%) 15 (37.5)
Performance status, ≥ 1 17 (42.5)
Sum of tumor diameters (mm), median [range] 82 [11–169]
Tumor related symptoms at baseline, yes (%) 24 (60)
Thyroglobulin doubling time, year 0.7 (0.12–3.0)
Treatment period (months), median [range] 29.5 [6.8–61.5]
Observation period (months), median [range] 32.5 [7.4–61.5]
Dose Intensity, median [range] 9.6 [4.0–16.4]
Best response in RECIST criteria, PR (%) 29 (72.5)
eGFR at baseline (mL/min/1.73 m2), median [range] 72.2 (43.6–119.1)
Proteinuria grade 1 at baseline, yes (%) 2 (5)
Past hypertension history (%) 24 (60)
Past diabetes mellitus history (%) 3 (7.5)
Past renal history (%) 6 (15)
Renal metastasis, baseline (%) 3 (7.5)
latest (%) 3 (7.5)
Liver metastasis, baseline (%) 5 (12.5)
latest (%) 7 (17.5)
Proteinuria grade 3, yes (%) 21 (52.5)
Treatment continuation, yes (%) 20 (50)
Treatment termination due to renal problem, yes (%) 7 (17.5)